GlycA — новый биомаркер воспалительных, онкологических, сердечно-сосудистых заболеваний, и предиктор смерти, независимо от причин, её вызывающих

  • Борис Ильич Кузник Читинская государственная медицинская академия, Чита
Ключевые слова: GlycA, воспалительные заболевания, сердечно-сосудистые заболевания, онкологические заболевания, диабет 2 типа, предиктор смерти.

Аннотация

В обзоре представлены данные о недавно (2015 г.) выявленном предикторе смерти, независимо от причин её вызывающих. На роль предиктора смерти претендует продукт ацетилирования гликопротеинов — GlycA (N-acetylglucosamine/galactosamine). Обсуждаются тонкие механизмы действия GlycA при воспалении, сердечно-сосудистой патологии, онкологических заболеваниях и диабете 2-го типа. Выявлены тесные корреляционные связи между содержанием GlycA и резистентностью к инсулину. С возрастом и увеличением массы тела (ИМТ) содержание GlycA повышается. Высокие концентрации GlycA обратно пропорциональны объему памяти и скорости обработки информации.

Скачивания

Данные скачивания пока не доступны.

Литература

1. Ritchie S.C., Wurtz P., Nath AP. et al. The biomarker GlycA is associated with chronic inflammation and predicts long-term risk of severe infection. Cell Systems. 2015. 1:1-9. doi:10.1016/j.cels.2015.09.007.

2. Otvos D., Wolak-Dinsmore, Shalaurova I., J. et al. GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin. Chem. 2015; 61: 714-23.

3. Alla-Korpela M. Serum nuclear magnetic resonance spectroscopy one more step toward clinical utility. Clin. Chemj. 2015; 61: 681-3.

4. Dullaart R.P., Gruppen E.G., Connelly M.A. et al. GlycA, a biomarker of inflammatory glycoproteins, is more closely related to the leptin/adiponectin ratio than to glucose tolerance status. Clin. Biochem. 2015; 48: N12, 811-4.

5. Ormseth M.J., Chung C.P., Oeser A.M. et al. Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis. Arthritis Res. Ther. 2015; 17: 117-25.

6. Gruppen E.G., Riphagen I.J., Connelly M.A. et al. GlycA, a Pro-Inflammatory Glycoprotein Biomarker, and Incident Cardiovascular Disease: Relationship with C-Reactive Protein and Renal Function. PLoS One. 2015; 23; 10(9):e0139057. doi: 10.1371/journal.pone.0139057.eCollection 2015.

7. Gruppen E.G., Connelly M.A., Otvos J.D. et al. A novel protein glycan biomarker and LCAT activity in metabolic syndrome. Eur. J. Clin. Investig. 2015; 45: 850-9.

8. Gruppen E.G., Connelly M.A., Vart P. et al. GlycA, a novel proinflammatory glycoprotein biomarker, and high-sensitivity C-reactive protein are inversely associated with sodium intake after controlling for adiposity: the Prevention of Renal and Vascular End-Stage Disease study. Am J Clin Nutr. 2016; Jun 15. pii: ajcn133744.

9. McGarrah R.W., Kelly J.P., Craig D.M. et al. A Novel Protein Glycan-Derived Inflammation Biomarker Independently Predicts Cardiovascular Disease and Modifies the Association of HDL Subclasses with Mortality. Clin Chem. 2017; 63(1): 288-96. doi: 10.1373/clinchem.2016.261636.

10. Lawler P.R., Akinkuolie A.O., Chandler P.D. et al. Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk. Circ Res. 2016; 1; 118(7): 1106-15.

11. Akinkuolie A.O., Pradhan A.D., Buring J.E. Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2015; 35: N6: 1544-50.

12. Durcan L, Winegar DA, Connelly MA et al. Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine. Therapy J Rheumatol. 2016 Apr;43(4):745-50. doi: 10.3899/jrheum.150437. Epub 2016 Feb 1.

13. Chung CP, Ormseth MJ, Connelly MA et al. GlycA, a novel marker of inflammation, is elevated in systemic lupus erythematosus. Lupus. 2016; 25: N3:296-300.

14. Jago R, Drews KL, Otvos JD et al. Novel measures of inflammation and insulin resistance are related to obesity and fitness in a diverse sample of 11-14 year-olds: The HEALTHY study Int J Obes (Lond). 2016; May 4. doi: 10.1038/ijo.2016.84.

15. Connelly MA, Gruppen EG, Wolak-Dinsmore J, Matyus SP, Riphagen IJ, Shalaurova I, Bakker SJ, Otvos JD, Dullaart RP. GlycA, a marker of acute phase glycoproteins, and the risk of incident type 2 diabetes mellitus: PREVEND study. Clin Chim Acta. 2016;Jan 15;452:10-7. doi: 10.1016/j.cca.2015.11.001. Epub 2015 Nov 5.

16. Gruppen EG, Connelly MA, Dullaart RP. Higher circulating GlycA, a pro-inflammatory glycoprotein biomarker, relates to lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in diabetic or metabolic syndrome subjects. J Clin Lipidol. 2016;10: N3:512-8.

17. Duprez D.A., Otvos J., Sanchez O.A. et al. Comparison of the Predictive Value of GlycA and Other Biomarkers of Inflammation for Total Death, Incident Cardiovascular Events, Noncardiovascular and Noncancer Inflammatory-Related Events, and Total Cancer Events. Clin Chem. 2016; May 12. pii: clinchem.2016.255828.

18. Dungan K., Binkley P., Osei K. GlycA is a Novel Marker of Inflammation Among Non-Critically Ill Hospitalized Patients with Type 2 Diabete. Inflammation. 2015;38: N3:1357-63.

19. Lorenzo C., Festa A., Hanley A.J. et al. Novel Protein Glycan-Derived Markers of Systemic Inflammation and C-Reactive Protein in Relation to Glycemia, Insulin Resistance, and Insulin Secretion. Diabetes Care. 2016; Dec 28. pii: dc161569. doi: doi: 10.2337/dc16-1569.

20. Akinkuolie A.O., Pradhan A.D., Buring J.E. Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2015;35: N6:1544-50.

21. Bartlett D.B., Connelly M.A., AbouAssi H. et al. A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls. Arthritis Res Ther. 2016; Apr 12;18:86. doi: 10.1186/s13075-016-0982-5.

22. Chandler P.D., Akinkuolie A.O., Tobias D.K. et al. Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality. LoS One. 2016; Nov 30;11(11):e0165615. doi: 10.1371/journal.pone.0165615.

23. Connelly M.A., Shimizu C., Winegar D.A. et al. Differences in GlycA and lipoprotein particle parameters may help distinguish acute kawasaki disease from other febrile illnesses in children. BMC Pediatr. 2016 Sep 5;16(1):151. doi: 10.1186/s12887-016-0688-5.

24. Connelly M.A., Shalaurova I., Otvos J.D. High-density lipoprotein and inflammation in cardiovascular disease. Transl Res. 2016 Jul;173:7-18.

25. Joshi A.A., Lerman J.B., Aberra T.M. et al. GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis. Circ Res. 2016 Nov 11;119(11):1242-1253.

26. Cohen-Manheim I., Doniger G.M., Sinnreich R. et al. Increase in the Inflammatory Marker GlycA over 13 Years in Young Adults Is Associated with Poorer Cognitive Function in Midlife. PLoS One. 2015 Sep 25;10(9):e0138036. doi: 10.1371/journal.pone.0138036. eCollection 2015.
Опубликован
2017-12-18
Как цитировать
Кузник Б. И. GlycA — новый биомаркер воспалительных, онкологических, сердечно-сосудистых заболеваний, и предиктор смерти, независимо от причин, её вызывающих // Патологическая физиология и экспериментальная терапия. 2017. Т. 61. № 4. С. 136-141.
Раздел
Обзоры